Lead Sponsor

Sanofi

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
•Histologically or cytologically documented metastatic, measurable adenocarcinoma of the colon, rectum, or appendix with no prior therapies for metastatic disease
•ECOG performance status (PS) of 0 or 1
•Adequate hematologic, renal, and hepatic function as defined by required baseline laboratory parameters
•No other serious concomitant disease.

•Peripheral neuropathy \> Grade 1 at baseline
•History of significant cerebrovascular, cardiovascular, or peripheral vascular disease
•Uncontrolled hypertension (defined as blood pressure \> 150/100 mmHg)
•History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, within 6 months prior to start of study drug
•Minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to start of study drug
•Serious, non-healing wound, ulcer, or bone fracture
•Active gastroduodenal ulcer
•Evidence of bleeding diathesis or coagulopathy
•Significant history of bleeding within 6 months prior to registration
•Prior history of hypertensive crisis or hypertensive encephalopathy

Related studies

NCT07417488 · Colorectal Cancer, Small Bowel Adenocarcinoma

NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more

NCT06728072 · Colorectal Cancer, CRC

NCT06205836 · Colorectal Cancer

NCT06307548 · Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, and more

CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer